A review of economic evaluations of genetic testing services and interventions (2004-2009)

Sandjar Djalalov, Zahra Musa, Michael Mendelson, Katherine Siminovitch, Jeffrey S Hoch

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

To review economic evaluations of genetic interventions published between 2004 and 2009 and assess the quality of the identified studies, we searched for economic evaluations of genetic testing and interventions published between 2004 and 2009. Studies that met inclusion criteria were reviewed and their quality then assessed using a validated instrument-the Quality of Health Economic Studies. Of 54 articles identified, 26 met study criteria and were included in the review. These studies span a number of clinical indications, genetic tests, and interventions, but the majority (92%) focuses on genetic interventions for preventive screening and increasing treatment efficacy. The mean quality score for the reviewed studies was 89.8. Comparison of the quality of different study types revealed that cost-utility studies and studies that used a combined decision tree and Markov model had the highest mean quality scores. Clear statements regarding bias, funding source, and study perspective were commonly lacking in the reviewed studies. Although the reviewed studies were of fairly high quality, we found Quality of Health Economic Studies methodology for grading the quality of economic evaluations challenging and observed no statistically significant improvement in quality of studies between the periods of 1995-2004 and 2004-2009.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalGenetics in Medicine
Volume13
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Genetic Services
Genetic Engineering
Genetic Testing
Cost-Benefit Analysis
Economics
Decision Trees
Health
Quality Improvement
Costs and Cost Analysis

Keywords

  • cost-effectiveness analysis
  • economic evaluation
  • genetic testing
  • personalized medicine
  • quality assessment

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

A review of economic evaluations of genetic testing services and interventions (2004-2009). / Djalalov, Sandjar; Musa, Zahra; Mendelson, Michael; Siminovitch, Katherine; Hoch, Jeffrey S.

In: Genetics in Medicine, Vol. 13, No. 2, 02.2011, p. 89-94.

Research output: Contribution to journalReview article

Djalalov, Sandjar ; Musa, Zahra ; Mendelson, Michael ; Siminovitch, Katherine ; Hoch, Jeffrey S. / A review of economic evaluations of genetic testing services and interventions (2004-2009). In: Genetics in Medicine. 2011 ; Vol. 13, No. 2. pp. 89-94.
@article{9cd83ad2cd12410a906fa14d9063c141,
title = "A review of economic evaluations of genetic testing services and interventions (2004-2009)",
abstract = "To review economic evaluations of genetic interventions published between 2004 and 2009 and assess the quality of the identified studies, we searched for economic evaluations of genetic testing and interventions published between 2004 and 2009. Studies that met inclusion criteria were reviewed and their quality then assessed using a validated instrument-the Quality of Health Economic Studies. Of 54 articles identified, 26 met study criteria and were included in the review. These studies span a number of clinical indications, genetic tests, and interventions, but the majority (92{\%}) focuses on genetic interventions for preventive screening and increasing treatment efficacy. The mean quality score for the reviewed studies was 89.8. Comparison of the quality of different study types revealed that cost-utility studies and studies that used a combined decision tree and Markov model had the highest mean quality scores. Clear statements regarding bias, funding source, and study perspective were commonly lacking in the reviewed studies. Although the reviewed studies were of fairly high quality, we found Quality of Health Economic Studies methodology for grading the quality of economic evaluations challenging and observed no statistically significant improvement in quality of studies between the periods of 1995-2004 and 2004-2009.",
keywords = "cost-effectiveness analysis, economic evaluation, genetic testing, personalized medicine, quality assessment",
author = "Sandjar Djalalov and Zahra Musa and Michael Mendelson and Katherine Siminovitch and Hoch, {Jeffrey S}",
year = "2011",
month = "2",
doi = "10.1097/GIM.0b013e3182003294",
language = "English (US)",
volume = "13",
pages = "89--94",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A review of economic evaluations of genetic testing services and interventions (2004-2009)

AU - Djalalov, Sandjar

AU - Musa, Zahra

AU - Mendelson, Michael

AU - Siminovitch, Katherine

AU - Hoch, Jeffrey S

PY - 2011/2

Y1 - 2011/2

N2 - To review economic evaluations of genetic interventions published between 2004 and 2009 and assess the quality of the identified studies, we searched for economic evaluations of genetic testing and interventions published between 2004 and 2009. Studies that met inclusion criteria were reviewed and their quality then assessed using a validated instrument-the Quality of Health Economic Studies. Of 54 articles identified, 26 met study criteria and were included in the review. These studies span a number of clinical indications, genetic tests, and interventions, but the majority (92%) focuses on genetic interventions for preventive screening and increasing treatment efficacy. The mean quality score for the reviewed studies was 89.8. Comparison of the quality of different study types revealed that cost-utility studies and studies that used a combined decision tree and Markov model had the highest mean quality scores. Clear statements regarding bias, funding source, and study perspective were commonly lacking in the reviewed studies. Although the reviewed studies were of fairly high quality, we found Quality of Health Economic Studies methodology for grading the quality of economic evaluations challenging and observed no statistically significant improvement in quality of studies between the periods of 1995-2004 and 2004-2009.

AB - To review economic evaluations of genetic interventions published between 2004 and 2009 and assess the quality of the identified studies, we searched for economic evaluations of genetic testing and interventions published between 2004 and 2009. Studies that met inclusion criteria were reviewed and their quality then assessed using a validated instrument-the Quality of Health Economic Studies. Of 54 articles identified, 26 met study criteria and were included in the review. These studies span a number of clinical indications, genetic tests, and interventions, but the majority (92%) focuses on genetic interventions for preventive screening and increasing treatment efficacy. The mean quality score for the reviewed studies was 89.8. Comparison of the quality of different study types revealed that cost-utility studies and studies that used a combined decision tree and Markov model had the highest mean quality scores. Clear statements regarding bias, funding source, and study perspective were commonly lacking in the reviewed studies. Although the reviewed studies were of fairly high quality, we found Quality of Health Economic Studies methodology for grading the quality of economic evaluations challenging and observed no statistically significant improvement in quality of studies between the periods of 1995-2004 and 2004-2009.

KW - cost-effectiveness analysis

KW - economic evaluation

KW - genetic testing

KW - personalized medicine

KW - quality assessment

UR - http://www.scopus.com/inward/record.url?scp=79951569002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951569002&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e3182003294

DO - 10.1097/GIM.0b013e3182003294

M3 - Review article

C2 - 21273949

AN - SCOPUS:79951569002

VL - 13

SP - 89

EP - 94

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 2

ER -